Merck & Co., Inc.
Search results
Apr 2, 2024 · Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.
Roivant builds nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Our Vants have conducted 10 positive Phase 3 trials since 2019, and launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults.
Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy .
Our pipeline includes innovative product candidates across numerous therapeutic areas including immunology, oncology, hematology, and dermatology. Filter. Topical · Dermavant.
Find the latest Roivant Sciences Ltd. (ROIV) stock quote, history, news and other vital information to help you with your stock trading and investing.
Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology companies.
Dec 1, 2022 · Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology companies.
Jun 28, 2022 · Roivant reported $2.1B in cash and cash equivalents and reprioritized pipeline to focus on most meaningful opportunities while maintaining the financial flexibility to opportunistically in-license assets
Jun 28, 2022 · NEW YORK--(BUSINESS WIRE)-- Roivant Sciences and Pfizer today announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality.
Jun 2, 2024 · Roivant Sciences' stock is undervalued with a market cap of $8.37 billion and $6 billion in cash. The company holds stakes in biotech companies worth billions, including Immunovant and Arbutus.
